<DOC>
	<DOCNO>NCT00824590</DOCNO>
	<brief_summary>This study compare pharmacokinetics Dimebon subject severe renal impairment subject normal renal function oral administration single oral 20-mg dose Dimebon . This study also assess safety tolerability single oral 20-mg dose Dimebon subject severe renal impairment subject normal renal function .</brief_summary>
	<brief_title>A Phase 1 , Non-Randomized , Open-Label , Single-Dose Study To Evaluate The Pharmacokinetics , Safety , And Tolerability Of Dimebon PF 01913539 In Subjects With Severely-Impaired And Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Male and/or female subject age 18 75 year , inclusive For severe renal impairment group , subject creatinine clearance le 30 mL/min , yet dialysis good general health commensurate population chronic renal disease ; however , subject type 1 2 diabetes reasonably control predisposition severe hypoglycemia include . For normal renal function group , healthy subject creatinine clearance great 80mL/min demographically comparable subject impair renal function Pregnant nursing woman ; woman childbearing potential ( WOCBP ) unwilling unable use acceptable method contraception outline protocol least 14 day prior first dose study medication . For normal renal function group , use prescription nonprescription drug , vitamin , dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose study medication . Acetaminophen dose â‰¤ 2 grams/day permit . For renal impairment group , know history clinically significant coronary heart disease , cerebrovascular disease peripheral vascular disease and/or event/intervention past 6 month . Systemic therapy CYP3A CYP2D6 inhibitor within 7 day 5 halflives ( whichever longer ) prior first dose trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Dimebon</keyword>
	<keyword>renal impairment</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>